These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9035702)

  • 1. Early clinical development of tazarotene.
    Marks R
    Br J Dermatol; 1996 Oct; 135 Suppl 49():26-31. PubMed ID: 9035702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis.
    Weinstein GD
    Br J Dermatol; 1996 Oct; 135 Suppl 49():32-6. PubMed ID: 9035703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tazarotene gel: efficacy and safety in plaque psoriasis.
    Weinstein GD
    J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S33-8. PubMed ID: 9270554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis.
    Krueger GG; Drake LA; Elias PM; Lowe NJ; Guzzo C; Weinstein GD; Lew-Kaya DA; Lue JC; Sefton J; Chandraratna RA
    Arch Dermatol; 1998 Jan; 134(1):57-60. PubMed ID: 9449910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.
    Lebwohl M; Ast E; Callen JP; Cullen SI; Hong SR; Kulp-Shorten CL; Lowe NJ; Phillips TJ; Rosen T; Wolf DI; Quell JM; Sefton J; Lue JC; Gibson JR; Chandraratna RA
    J Am Acad Dermatol; 1998 May; 38(5 Pt 1):705-11. PubMed ID: 9591815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical safety of tazarotene in the treatment of plaque psoriasis.
    Marks R
    J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S25-32. PubMed ID: 9270553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis.
    Tang-Liu DD; Matsumoto RM; Usansky JI
    Clin Pharmacokinet; 1999 Oct; 37(4):273-87. PubMed ID: 10554045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tazarotene--first of a new generation of receptor-selective retinoids.
    Chandraratna RA
    Br J Dermatol; 1996 Oct; 135 Suppl 49():18-25. PubMed ID: 9035701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect.
    Weinstein GD; Krueger GG; Lowe NJ; Duvic M; Friedman DJ; Jegasothy BV; Jorizzo JL; Shmunes E; Tschen EH; Lew-Kaya DA; Lue JC; Sefton J; Gibson JR; Chandraratna RA
    J Am Acad Dermatol; 1997 Jul; 37(1):85-92. PubMed ID: 9216528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tazarotene in combination with phototherapy.
    Koo JY
    J Am Acad Dermatol; 1998 Oct; 39(4 Pt 2):S144-8. PubMed ID: 9777793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tazarotene--a topical retinoid for psoriasis.
    Drug Ther Bull; 1999 Jun; 37(6):47-8. PubMed ID: 10692712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis.
    Chandraratna RA
    J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S12-7. PubMed ID: 9270551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy.
    Tanghetti E; Lebwohl M; Stein Gold L
    J Drugs Dermatol; 2018 Dec; 17(12):1280-1287. PubMed ID: 30586259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tazarotene: a review of its pharmacological profile and potential for clinical use in psoriasis.
    Duvic M
    Expert Opin Investig Drugs; 1997 Oct; 6(10):1537-51. PubMed ID: 15989518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obtaining the optimal treatment outcome with tazarotene.
    McClelland PB
    Dermatol Nurs; 1998 Oct; 10(5):343-8. PubMed ID: 9873273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor-selective retinoids for psoriasis: focus on tazarotene.
    Weindl G; Roeder A; Schäfer-Korting M; Schaller M; Korting HC
    Am J Clin Dermatol; 2006; 7(2):85-97. PubMed ID: 16605289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Instrumental evaluation of retinoid-induced skin irritation.
    Stücker M; Hoffmann M; Altmeyer P
    Skin Res Technol; 2002 May; 8(2):133-40. PubMed ID: 12060479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and safety of tazarotene: optimizing clinical results.
    Lebwohl M
    Cutis; 1998 Feb; 61(2 Suppl):27-9. PubMed ID: 9787989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis.
    Tzaneva S; Hönigsmann H; Tanew A; Seeber A
    Br J Dermatol; 2002 Oct; 147(4):748-53. PubMed ID: 12366423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tazarotene.
    Foster RH; Brogden RN; Benfield P
    Drugs; 1998 May; 55(5):705-11; discussion 712. PubMed ID: 9585866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.